Related Articles
Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway
UII/GPR14 is involved in NF-κB-mediated colonic inflammation in vivo and in vitro
The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
Urantide prevents CCl4‑induced acute liver injury in rats by regulating the MAPK signalling pathway
Urotensin II promotes the proliferation of endothelial progenitor cells through p38 and p44/42 MAPK activation